Impressive Vertex hepatitis C drug data unveiled

November 1, 2008 - A closely watched hepatitis C treatment being developed by Vertex Pharmaceuticals Inc showed an impressive ability to knock out the virus in patients who failed other treatments and those not previously treated for the serious liver disease, data from mid-stage studies show.

U.S. hepatitis A vaccine rates vary widely

January 25, 2012 — NEW YORK (Reuters Health) - Although about 85 percent of kids in two U.S. states have had a complete set of hepatitis A vaccines, overall just three in 10 have had both shots, according to a new survey from the Centers for Disease Control and Prevention (CDC).

Device makers urge coverage of weight-loss surgery

January 25, 2012 — CHICAGO (Reuters) - Device manufacturers are pushing the U.S. government and health insurers to cover weight-loss surgery, an effort that could give millions more obese Americans access to the treatments.

Arsenic cancer risk still high decades later

January 24, 2012 — NEW YORK (Reuters Health) - People exposed to very high levels of arsenic in Chilean drinking water back in the 1950s and 60s are still showing a higher-than-normal risk of bladder cancer -- years after the arsenic problem was brought under control, a new study shows.